1344669-72-2Relevant academic research and scientific papers
TREATMENT OF CNS DISEASES WITH SGC STIMULATORS
-
Paragraph 00151, (2018/05/27)
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5'-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
Acidic triazoles as soluble guanylate cyclase stimulators
Roberts, R. Lee,Bradley, A. Paul,Bunnage, E. Mark,England, S. Katherine,Fobian, M. Yvette,Fox, N.A. David,Gymer, Geoff E.,Heasley, Steven E.,Molette, Jerome,Smith, Graham L.,Fairman, David,Schmidt, Michelle A.,Tones, Michael A.,Dack, Kevin N.
, p. 6515 - 6518 (2011/12/04)
A series of acidic triazoles with activity as soluble guanylate cyclase stimulators is described. Incorporation of the CF3 triazole improved the overall physicochemical and drug-like properties of the molecule and is exemplified by compound 25.
